Status:
UNKNOWN
Early Prostate Cancer: Predicting Treatment Response
Lead Sponsor:
University of California, Irvine
Collaborating Sponsors:
University of California, Los Angeles
Cedars-Sinai Medical Center
Conditions:
Prostate Cancer
Eligibility:
MALE
18-90 years
Brief Summary
This study will replicate/validate the risk prediction model developed for the Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) study in a more diverse patient population to assess...
Detailed Description
The study will contribute a replicable model for improving risk prediction from patient characteristics, clinical severity indicators, and genomic tests to aid in personalizing treatment. The proposed...
Eligibility Criteria
Inclusion
- 18 - 90 years of age
- Prostate-Specific Antigen (PSA) values \<50ng/ml
- Clinical stage of T1 or T2
- No evidence of metastasis or nodal involvement
Exclusion
- Age 91 or greater
- Clinically locally advanced or metastatic disease
- PSA equal to or greater than 50ng/ml
- Diagnosis of malignancy (excluding squamous or basal cell carcinoma of the skin) within 3 years of diagnosis of prostate cancer
Key Trial Info
Start Date :
January 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2021
Estimated Enrollment :
693 Patients enrolled
Trial Details
Trial ID
NCT03770351
Start Date
January 1 2017
End Date
July 1 2021
Last Update
April 9 2021
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, Irvine
Irvine, California, United States, 92697
2
Veterans Affair Long Beach Healthcare System
Long Beach, California, United States, 90822
3
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90048
4
University of California, Los Angeles
Los Angeles, California, United States, 90095